Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Completed · Phase 2

Conditions studied: Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes, Myeloid Metaplasia, Lymphoma

In brief

The purpose of this phase II study is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies.

Key facts

Study ID

NCT00086125

Run by

Merck Sharp & Dohme LLC

People needed

57

Starts

2004-06-01

Expected to finish

2006-06-01

Last updated by the study team

2015-08-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Chicago Hospitals, Section of Hematology/Oncology — Chicago, Illinois, United States
• Washington University School of Medicine, Siteman Cancer Center, 4921 Parkview Place — St Louis, Missouri, United States
• The Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
• New York Presbyterian Hospital, Weill College of Cornell University — New York, New York, United States
• Morris Cancer Center - Duke University Medical Center, Adult Bone Marrow Transplant Clinic — Durham, North Carolina, United States
• Gabrail Cancer Center — Canton, Ohio, United States
• Jeane's Hospital of TUHS — Philadelphia, Pennsylvania, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.